An international, randomized, double-blind, placebo-controlled Phase III study—the largest of its kind for mpox—found that tecovirimat did not improve clinical outcomes for adults with clade II mpox ...
Orforglipron, a novel oral nonpeptide GLP-1 receptor agonist (RA), led to a greater reduction in A1c and more significant weight loss compared to oral semaglutide in patients with type 2 diabetes (T2D ...
Pivotal study shows no clear benefit for the common endoscopic procedure in this patient group. Experts say the new data ...
The results of a randomized controlled trial (RCT) indicate that meningococcal B vaccine is not effective at preventing ...
A randomized trial of hospitalized patients with moderate hyponatremia compared targeted sodium correction versus routine care on mortality and rehospitalization rates.
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial Patients with advanced lung cancer reporting at least moderate ...
Hand-foot syndrome (HFS) is a dose-limiting side effect of capecitabine. Celecoxib prevents HFS by inhibiting cyclooxygenase-2 (COX-2) that is upregulated because of the underlying associated ...
When Elise Felicione tried to design a clinical trial for a supplement, 5 things got in the way. It’s a lesson for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results